Trial Profile
An Open-Label Single-Arm Phase 1 Study Evaluating Safety of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Itacitinib (Primary) ; Methylprednisolone; Prednisolone
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 02 Mar 2020 Status changed from recruiting to completed.
- 19 Jun 2019 Planned End Date changed from 1 Aug 2019 to 1 Feb 2020.
- 19 Jun 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Feb 2020.